Avectas, a cell engineering technology business, and CCRM, a leader in developing and commercializing cell and gene therapies, have entered into a collaboration to accelerate the translation of Avectas’ non-viral cell engineering platform (Solupore) into the clinic.   Cell and gene therapies offer the potential to dramatically transform the treatment of diseases, including cancer, for millions of patients worldwide. However, a global viral vector shortfall could halt progress in the indust...